Abstract
Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myeloid leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. Based on its involvement in CML pathogenesis, we hypothesized that KIT may govern responses of CML cells to imatinib. To test this, we assessed the growth of primary CML progenitor cells under conditions of sole BCR-ABL1, sole KIT and dual BCR-ABL1/KIT inhibition. Sole BCR-ABL1 inhibition suppressed mature CML progenitor cells, but these effects were largely abolished by stem cell factor (SCF) and maximal suppression required dual BCR-ABL1/KIT inhibition. In contrast, KIT inhibition did not add to the effects of BCR-ABL1 inhibition in primitive progenitors, represented by CD34 + 38 -cells. Long term culture-initiating cell (LTC-IC) assays on murine stroma revealed profound depletion of primitive CML cells by sole BCR-ABL1 inhibition despite the presence of SCF, suggesting primitive CML cells are unable to use SCF as a survival factor upon BCR-ABL1 inhibition. In CD34 + 38 + cells, SCF strongly induced pAKT S473 in a phosphatidylinositol 3' kinase (PI3K)-dependent manner, which was further enhanced by inhibition of BCR-ABL1 and associated with increased colony survival. In contrast, pAKT S473 levels remained low in CD34 + 38 -cells cultured under the same conditions. Consistent with reduced response to SCF, KIT surface expression was significantly lower on CD34 + 38 -compared to CD34 + 38 + CML cells, suggesting a possible mechanism for the differential effects of SCF on mature and primitive CML progenitor cells.
Introduction
The BCR-ABL1 tyrosine kinase inhibitor (TKI), imatinib, induces profound responses in most patients with newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) (1) . Imatinib inhibition of BCR-ABL1 correlates with response, and reactivation of BCR-ABL1 signaling by kinase point mutations with relapse (2) . In addition to BCR-ABL1, imatinib targets the tyrosine kinases ABL1, KIT, ARG (ABL2), DDR1/2, PDGFR, CSF-1R, and LCK (2) (3) (4) . In contrast to BCR-ABL1, we detected no mutations in KIT or PDGFR in patients with imatinib resistance (5).
Imatinib's capacity to inhibit non-BCR-ABL1 targets has expanded its utility to malignancies driven by mutations of KIT or PDGFR (6, 7) , but inhibition of physiological kinase signaling within normal cells may be the cause of side effects such as anemia (8) , myelosuppression (9) and fluid retention (10) . It is largely unknown whether co-inhibition of non-BCR-ABL1 targets within CML cells has therapeutic benefits.
KIT has been implicated in CML pathogenesis. BCR-ABL1 expressing progenitors were shown to be hypersensitive to stem cell factor (SCF) due to BCR-ABL1-induced upregulation of its receptor, KIT, (11, 12) (11, 12) (11, 12) (11, 12) (11, 12) (11, 12) (11, 12) and SCF was reported to support growth of cytokine-dependent CML but not normal progenitors (13) . Furthermore, culture of CML stem and progenitor cells on SCF-deficient stroma favors normal progenitors, suggesting CML progenitors may be more SCF responsive than their normal counterparts (14) . Accordingly, KIT-expressing BCR-ABL1-transduced murine myeloid cells were less sensitive to sole inhibition of either BCR-ABL1 or KIT compared to simultaneous inhibition of both kinases (15) . In primary CML CD34 + cells, SCF reduced apoptosis in response to nilotinib (16) , but it is unknown which specific pathways are activated by SCF to confer relative TKI resistance, and whether the requirement for KIT inhibition extends to more primitive CML cells. We sought to determine the contribution of KIT inhibition to the effects of TKIs on CML cells at various differentiation stages. We find that dual inhibition of BCR-ABL1 and KIT is required for suppression of mature but not primitive CML progenitors. This differential effect is due to the inability of primitive CML cells to activate AKT in response to SCF upon inhibition of BCR-ABL1.
Materials And Methods

Patient samples
Bone marrow or leukapheresis was obtained from newly diagnosed CML-CP patients. All patients provided informed consent to research protocols approved by the Institutional Review Boards of the participating institutions. Normal bone marrow mononuclear cells (MNC) were from AllCells (Emeryville, CA). Cell selection was as described (17) (details in Supplementary Methods).
Inhibition of BCR-ABL1, KIT, mitogen-activated ERK kinase (MEK) and phosphatidyl inositol 3' kinase (PI3K)
Sole BCR-ABL1 inhibition was achieved with PPY-A (a gift of ARIAD Pharmaceuticals, Boston, MA) (18) . Sole KIT inhibition was achieved by three methods: (a) use of a SCF-blocking antibody K44.2
(SCF-block, Sigma Aldrich, St. Louis, MO), a human-specific antibody that binds extracellularly to KIT and prevents SCF-induced dimerization; (b) BAW667, a small molecule that targets KIT but not BCR-ABL1, the chemical structure of which is still proprietary. The activity profile of BAW667 was determined as previously described (19, 20) and is provided in Supplementary 
Immunoblot analysis of cell lines and patient samples
Analysis of primary cells and cell lines was as previously published (17, 21) . For details and a list of antibodies see Supplementary Methods.
Colony assays
Hematopoietic colony forming assays were performed as described (17) . For details see Supplementary
Methods.
Long-term culture-initiating cell (LTC-IC) assays
Murine M210B4 stromal cells plated at 5 x 10 4 cells/well in a 24-well format were irradiated with 40 Gy.
10
4 Lin-depleted CML cells were cultured in triplicate wells in LTC-IC media (IMDM, horse serum, FBS, hydrocortisone) in the following conditions: untreated, 2 μM imatinib, 1 μM PPY-A, 200 ng/mL SCF-block, 1 μM PPY-A+200 ng/mL SCF-block. The medium was supplemented with 5 ng/mL human SCF. Half medium changes were performed weekly and included inhibitors at the relevant concentrations.
At intervals of one, three and six weeks, cells were detached with trypsin, plated in cytokinesupplemented methylcellulose (Stem Cell Technologies) and colony-forming cells (CFC) were analyzed at 2 weeks. CFC frequencies for all patients are reported relative to starting cell number. Individual colonies (10 per condition or as many as available) were genotyped by FISH using a dual color/dual fusion BCR-ABL1 LSI probe (Abbott Molecular) (17) . Ph + CFC relative to untreated are reported.
Cell proliferation assays
Viable cells were quantified using MTS as described (21 
Quantitative RT-PCR for SCF
Details are described in Supplementary Methods.
Results
Imatinib inhibits both BCR-ABL1 and KIT, PPY-A inhibits BCR-ABL1 but not KIT, and BAW667
inhibits KIT but not BCR-ABL1
We initially determined the specificity of imatinib, dasatinib, PPY-A (22), BAW667 (a compound with activity against KIT, but not BCR-ABL1) and a SCF-blocking antibody (SCF-block). 1A ). No KIT inhibition was seen with 10 μM PPY-A, while 10 μM BAW667 slightly reduced pBCR-ABL1 ( Supplementary Fig. 1 ). We concluded that PPY-A and BAW667 at 1 μM selectively inhibit BCR-ABL1 or KIT, respectively. SCF-block at 200ng/mL suppressed KIT phosphorylation without affecting BCR-ABL1 activity. Similar results were obtained in CD34 + CML cells, using CRKL as a marker for BCR-ABL1 activity (Fig. 1B) . KIT was phosphorylated in CML CD34 + cells in the absence of SCF and this phosphorylation was reduced by imatinib or BAW667, but not PPY-A, suggesting that some KIT activation occurs without SCF, independent of BCR-ABL1 kinase activity. The band corresponding to We initially compared CFU-GM colony formation upon sole BCR-ABL1 inhibition (PPY-A),
sole KIT inhibition (SCF-block) or dual BCR-ABL1/KIT inhibition (imatinib or PPY-A+SCF-block).
Cells were plated in IL-3, GM-CSF and SCF. Unlike imatinib, which reduced colonies by ~80%, PPY-A suppressed CFU-GM colony formation by only ~30% and SCF-block by ~50% ( Fig. 2A ). Dual BCR-ABL1 and KIT inhibition by PPY-A and SCF-block, however, reduced colony numbers by ~80%, suggesting that both BCR-ABL1 and SCF/KIT contribute independently to colony growth. Normal CFU-
GM colony formation was unaffected by sole BCR-ABL1 inhibition (PPY-A), but suppressed by imatinib
or SCF-block, consistent with dependence on KIT signaling. The lack of efficacy of PPY-A was not due to drug instability, since pCRKL was inhibited in PPY-A-treated colonies harvested following the culture period ( Fig. 2B ). We also tested inhibitor effects on BFU-E colony formation. PPY-A had no effect, while sole SCF-block reduced BFU-E colony numbers to those observed with imatinib (Supplementary Fig. 2A ). Thus, CML erythroid colony growth is independent of BCR-ABL1 and its suppression by imatinib is due entirely to KIT inhibition. Responses of normal BFU-E were identical, confirming that growth inhibition was cell-type rather than CML-specific. The insensitivity of CML BFU-E to PPY-A is not due to autocrine SCF production, since SCF is not expressed by CML CD34 + cells and not induced by PPY-A ( Supplementary Fig. 2B ).
In a second independent series of experiments we included BAW667 and shKIT as alternative means of suppressing KIT activity. CD34 + cells from CML patients or normal controls were plated with or without SCF and BAW667, PPY-A, BAW667+PPY-A, or imatinib were added ( increased CML and normal CFU-GM colonies by ~2.1-fold and ~1.7-fold, respectively. BAW667 abrogated the colony increase imparted by SCF in CML and normal cells. Additionally, BAW667
reduced CML colony formation in the absence of SCF by ~50%, while effects on normal colonies were minimal, suggesting that KIT is constitutively active in CML but not normal progenitor cells and contributes to their growth. PPY-A inhibited colony formation by CML progenitor cells, and this was partially rescued by SCF, but had no effect on normal progenitor cells. Combination of PPY-A and BAW667 had effects similar to imatinib. To specifically inhibit KIT without concerns about possible offtarget effects of biochemical inhibitors, we used a lentiviral vector for simultaneous expression of shKIT and GFP in human cells ( Supplementary Fig. 3 ). Without SCF, shKIT had little effect on normal cells, but reduced colony formation of CML CD34 + cells by ~45% ( Fig. 3B ), similar to BAW667 alone (Fig. 3A) .
shKIT also abrogated the increase in colony formation caused by SCF in both normal and CML CD34 + cells. Lastly, combining shKIT and PPY-A had similar effects as PPY-A+BAW667 or imatinib.
Altogether these data demonstrate that CML CD34 + progenitor cells are slightly more responsive to SCF than normal CD34 + cells and that KIT is intrinsically active in CML but not normal cells. As a result, KIT inhibition differentiates between normal and CML CD34 + progenitor cells in the presence and absence of SCF, and this differential is further increased by inhibition of BCR-ABL1.
For additional validation, we analyzed CML CFU-GM colony growth following removal of the individual cytokines SCF, GM-CSF or IL-3. We found that removal of SCF had the most pronounced effect; combining SCF removal with PPY-A had effects comparable to imatinib, suggesting that the differential sensitivity of CML CFU-GM to imatinib and PPY-A is due exclusively to their differential effects on KIT ( Supplementary Fig. 4A ,B). It should be noted that some colony growth is due to IL-3 or GM-CSF, evidenced by an ~15% reduction of colony growth upon removal of IL-3 or GM-CSF in the presence of PPY-A ( Supplementary Fig. 4A,B) . Removal of individual cytokines did not enhance PPY-A effects against BFU-E colony formation ( Supplementary Fig. 4C ), unsurprising given our finding that these cells are dependent on KIT but not BCR-ABL1. We also plated CML progenitors on murine stroma for 1, 3 or 6 weeks in the presence of PPY-A, SCF-block or both. Although precise assignment of these populations to a specific differentiation stage is difficult, the progressively longer duration of culture permits expansion and maturation of increasingly primitive cells that are quantified by CFC assays as a composite readout for survival, expansion and maturation (24) . Resulting colonies were genotyped for BCR-ABL1 by FISH. Neither sole BCR-ABL1
(PPY-A) nor sole inhibition of KIT (SCF-block) achieved the CFC suppression seen with dual inhibition by imatinib or PPY-A+SCF-block in week 1 and week 3 colonies (Fig. 4B,C) . In 6-week LTC-IC, representative of primitive CML progenitors and stem cells, sole BCR-ABL1 inhibition achieved >95% suppression of Ph + CFC (Fig. 4D ) and was comparable to imatinib (p=0.8), while minimal growth suppression of 6-week LTC-IC was observed with SCF-block (Fig. 4E) . Dependence on BCR-ABL1 and KIT progressively increased or decreased, respectively, with duration of growth on murine stroma ( 
4E
). FISH revealed a mix of CML and LTC-IC, typical of early CML-CP (25) . Although growth suppression was variable between patients and in some instances the absolute number of surviving colonies was small, Ph + colonies were observed in all treatment conditions. Either imatinib or PPY-A, but not SCF-block increased the proportion of Ph -6-week LTC-IC relative to untreated (Fig. 4F ). Altogether these data suggest that primitive cells are less dependent on KIT and more dependent on BCR-ABL1 and that the capacity of KIT signaling to rescue CML cells in the presence of sole BCR-ABL1 inhibition is largely restricted to mature CML progenitors.
Differences in sensitivity to KIT inhibition may depend on KIT expression
KIT has been implicated in CML pathogenesis, but it is not precisely known how KIT and BCR- (Fig. 5A-D) .
To further characterize interactions of KIT and BCR-ABL1 signaling we used Mo7ep210
BCR-ABL1 cells. SCF rescued Mo7ep210 BCR-ABL1 cells treated with PPY-A (Fig. 6A) , similar to colony assays of CML CD34 + cells (Fig. 3A) . Since KIT signals through several canonical pathways including PI3K and MEK (reviewed in (27)), we tested how BCR-ABL1 and KIT signaling influence activation of these pathways. Mo7ep210 BCR-ABL1 cells were treated with SCF ± prior PPY-A inhibition of BCR-ABL1
signaling. In the presence of active BCR-ABL1, KIT activation of AKT (downstream of PI3K) and ERK1/2 (downstream of MEK) was weak and short-lived. In contrast, strong and sustained activation of 
AKT and ERK1/2 occurred when BCR-ABL1 was inhibited (Fig. 6B) . Activation of AKT was associated with a reduction of Foxo3A (Supplementary Fig. 5 ). Co-treatment with a PI3K inhibitor (LY294002) completely and co-treatment with a MEK inhibitor (PD98059) partially inhibited SCF-mediated proliferation, suggesting the SCF signal is transmitted mainly via PI3K/AKT and enhanced by BCR-ABL1 inhibition (Fig. 6C) 
Discussion
Previous studies have implicated KIT in CML pathogenesis, suggesting the efficacy of TKIs such as imatinib may be due to their combined activity against BCR-ABL1 and KIT (13, 15, 28) . For example,
KIT
+ BCR-ABL1-transduced murine progenitor cells are more sensitive to dual inhibition of KIT and BCR-ABL1 than to inhibition of either kinase individually (15) . In another study SCF rescued CML CD34 + cells from nilotinib but not imatinib effects and ascribed the difference to nilotinib's relatively weaker anti-KIT activity (16) . However, it remained unknown which specific pathways are activated by SCF to confer relative TKI resistance and whether the requirement for KIT inhibition depends on the stage of differentiation. Here we use TKIs, shRNA and blocking antibodies to examine whether the complimentary activity of imatinib against both BCR-ABL1 and KIT contributes to its efficacy in mature and primitive primary CML cells.
Sole BCR-ABL1 inhibition with PPY-A modestly suppressed CML CFU-GM colony formation
in the presence of cytokines, while SCF-block caused a slightly more pronounced reduction ( Fig. 2A ).
This reduction was not exclusively dependent on active SCF signaling, as SCF-block ( Fig. 2A) or removal of SCF ( Supplementary Fig. 4A ) had quantitatively similar effects to BAW667 (Fig. 3A) or shKIT knockdown in SCF-free cultures (Fig. 3B ). These data show that KIT contributes to the proliferation of mature CML progenitors in the absence of ligand, in accord with previous reports in BCR-ABL1 expressing cell lines (26) . Consistent with this, we detected low levels of pKIT Y721 in serumstarved CML CD34 + cells that was reduced by imatinib and BAW667 (Fig. 1B) . The effects of BAW667 inhibition of KIT were maximal in cultures of CML CD34 + cells that were supplemented with SCF ( level of BCR-ABL1 kinase activity not detected by pCRKL immunoblots (29) or constitutive KIT activation that is independent of BCR-ABL1 kinase activity. Additionally, the band corresponding to pKIT Y721 was not completely abolished by BAW667 or imatinib (Fig. 1B) , suggesting that a kinase other than BCR-ABL1 or KIT may phosphorylate KIT on tyrosine 721, although this residue is generally regarded as an autophosphorylation site. For example, SRC family kinases have been shown to phosphorylate tyrosine 900 of KIT (30) . Additional studies will be required to distinguish between these two possibilities.
In contrast to the limited effects of targeting either BCR-ABL1 or KIT in isolation, simultaneous inhibition of both kinases dramatically reduced CML CFU-GM growth. Disruption of KIT signaling was achieved with four independent approaches (BAW667; SCF-block; SCF removal; KIT knockdown), all of which produced similar effects when combined with the BCR-ABL1 inhibitor PPY-A. Dual dependence of primary CML progenitor cells on BCR-ABL1 and KIT signaling is restricted to granulocyte precursors. Although erythroid progenitors express both BCR-ABL1 and KIT (31), erythroid colony formation was maximally suppressed by inhibition of KIT alone and independent of BCR-ABL1 activity, identical to normal BFU-E (Supplementary Fig. 2A ). Thus, imatinib suppression of leukemic BFU-E is due entirely to KIT inhibition and BCR-ABL1 expression in erythroid lineage cells is not synonymous with dependence on BCR-ABL1 (32) . Accordingly, erythrocytosis is not a feature of CML.
Unlike the balanced contribution of BCR-ABL1 and KIT inhibition to suppression of CFU-GM colonies, effects on primitive CML cells, defined either by a CD34 + 38 -phenotype (Fig. 4A) or LTC-IC functionality (Fig. 4B) were mostly due to BCR-ABL1 inhibition. In particular, in 6-week LTC-IC assays, which select primitive CML progenitor cells (24), both imatinib and PPY-A reduced Ph + LTC-IC colonies by >95%, consistent with an effect that requires inhibition of BCR-ABL1, but not KIT. On the surface, the capacity of sole BCR-ABL1 inhibition to suppress primitive CML cells seems to contradict reports by us and others that that CML stem cells are insensitive to BCR-ABL1 inhibitors (33, 34) .
Furthermore, previous studies reported only modest imatinib effects on CML LTC-IC (35, 36) . The on April 13, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from differences are readily explained by the fact that prior studies evaluated the effects of short-term (72-96 hours) drug treatment of CML progenitors followed by 6-week culture on stroma without TKIs. These assays demonstrate the inability of TKIs to effectively induce apoptosis in primitive cells, but do not reflect conditions of long-term imatinib treatment. In contrast, we examined how continuous suppression of BCR-ABL1, KIT or their combination throughout the 6-week culture period would affect LTC-IC outgrowth. Importantly, to generate an environment devoid of human cytokines, we performed the LTC-IC assays using unmanipulated murine (M210B4) stromal cells (i.e. not engineered to express human cytokines). Since most cytokines and chemokines are not cross-reactive between species (37), these conditions minimize extrinsic factors that might support CML stem cells despite BCR-ABL1 inhibition.
In these conditions, imatinib and PPY-A resulted in profound suppression of the most primitive cells.
Notably, the differential effects of sole BCR-ABL1 vs. sole KIT inhibition on mature vs. primitive CML progenitor cells were consistent irrespective of whether the cell populations were defined by immunophenotype (Fig. 4A) or functionality (Fig. 4B-F) . Given the overall profound effect of sole BCR-ABL1 inhibition on primitive CML progenitor cells, it is impossible to exclude a small contribution of KIT inhibition to the suppression of this population. Despite small numbers of colonies, in all samples Ph + LTC-IC survived in the presence of BCR-ABL1 inhibitors, consistent with reports of residual BCR-ABL1 + LTC-IC and CD34 + 38 -cells in patients with sustained molecular response to imatinib (38, 39) .
The differential sensitivity of mature and primitive CML progenitors to sole BCR-ABL1 vs.
combined BCR-ABL1/KIT inhibition suggested cell type specific differences in the response to SCF. We initially studied Mo7ep210 BCR-ABL1 cells and found that SCF rescued these cells from the effects of PPY-A inhibition of BCR-ABL1 (Fig. 6A) . While active BCR-ABL1 blunted SCF activation of AKT and MEK, key pathways downstream of KIT (27) , inhibition of BCR-ABL1 sensitized cells to SCF. SCF rescue was completely blocked by PI3K inhibition, but only partially by MEK inhibition, implicating PI3K/AKT as the critical pathway downstream of KIT (Fig. 6C) . Similar results were obtained in primary CML CD34 + cells: while PPY-A or SCF alone had little effect on pAKT S473 , their combination greatly increased pAKT S473 (Fig. 6D) . LY294002 abrogated the SCF-induced increase in colony formation (Fig. 6E) . In contrast, basal pAKT S473 in CD34 + 38 -cells was low, as previously reported in BCR-ABL1 expressing murine stem cells and CD34 + 38 -CML cells (17, 40) , unchanged upon PPY-A treatment and minimally increased by SCF alone or in combination with PPY-A (Fig. 7A) . This is in stark contrast to CD34 + 38 + CML cells (Fig. 6D) and suggests that the PPY-A sensitivity of CD34 + 38 -CML cells is due to their inability to strongly activate SCF signaling upon BCR-ABL1 inhibition, possibly reflecting the lower CD117 expression on CD34 + 38 -compared to CD34 + 38 + CML cells (Fig. 7B) . From the drug development perspective, it is important to consider whether there is benefit to inhibiting non-oncogenic targets, or whether 'surgical' inhibitors with the narrowest possible target spectrum are preferred. Amongst the second and third generation BCR-ABL1 inhibitors, dasatinib, nilotinib and ponatinib directly inhibit KIT, while bosutinib has no activity against KIT (42) . The clinical activity of bosutinib (43, 44) can be explained by its inhibitory activity toward SRC kinases, which play a critical role in KIT signaling (45, 46) . Altogether our data suggest that, in vivo, CML stem cells may 
